Delving into the Latest Updates on ST-899 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

PAF receptor

Mechanism

PAF receptor antagonists(Platelet activating factor receptor antagonists)

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication-

Inactive Indication

Shock, Septic

Originator Organization

Sigma-Tau Industrie Farmaceutiche Riunite SpA

Active Organization-

Inactive Organization

Sigma-Tau Industrie Farmaceutiche Riunite SpA

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

The effect of ST 899, a novel platelet-activating factor (PAF) receptor antagonist, on serum tumor necrosis factor (TNF), interleukin-6 (IL-6), and interferon-gamma (IFN-gamma) production as well as on lethality in an experimental endotoxin shock model was investigated in C57BL/6 mice. In this model, animals receiving 40 mg/kg lipopolysaccharide (LPS) (Escherichia coli 055:B5) intraperitoneally were pretreated with ST 899 administered according to two different schedules. ST 899 pretreatment dose dependently reduced the mortality induced by LPS injection. The PAF receptor antagonist was also able to reduce significantly the LPS-induced increase in serum TNF. Although serum IL-6 levels were not affected, we found that ST 899, when administered intraperitoneally 60 min and intravenously 10 min prior to LPS challenge, had a tendency (at higher doses) to decrease circulating IFN-gamma levels. It is suggested that ST 899 may be beneficial, in combination with current therapies, in the treatment of diseases that involve overproduction of PAF, TNF, and IFN-gamma such as septic shock.

100 Deals associated with ST-899

Login to view more data